A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant

Horgan, Claire; Kanellopoulos, Alexandros; Paneesha, Shankara; Kishore, Bhuvan; Lovell, Richard; Nikolousis, Emmanouil

doi:10.4081/hr.2019.7800

Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Case Report

25 February 2019

3 Pages

A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant

and

Hematology and Stem Cell Transplantation Department, Heart of England NHS Trust, Bordesley Green East, Birmingham B9 5SS, UK

Author to whom correspondence should be addressed.

Hematol. Rep.2019, 11(1), 7800;https://doi.org/10.4081/hr.2019.7800

Version Notes

Order Reprints

Abstract

A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor lymphocyte infusions following relapse 18 months post reduced intensity HLAA mismatch Campath conditioning allogeneic stem cell transplant.

Keywords:

acute myeloid leukaemia; FLT-3 mutation; azacitidine

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia

MPL Y252H and MPL F126fs Mutations in Essential Thrombocythemia: Case Series and Review of Literature